Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2023 · The Lancet Diabetes & Endocrinology · 36 citations
https://doi.org/10.1016/s2213-8587(23)00253-x
M
Matthew Harmer
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
38
Papers
239
Citations
8
h-index
8
i10-index
Matthew Harmer is an academic researcher from University Hospital Southampton NHS Foundation Trust. The author has contributed to research in topics: Dialysis and Renal Disease Management & Adolescent and Pediatric Healthcare & Childhood Cancer Survivors' Quality of Life. The author has an h-index of 8, co-authored 33 publications.
ORCID: 0000-0003-2977-0263Papers by this author
worksImmunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial
2024 · The Lancet Child & Adolescent Health · 33 citations
https://doi.org/10.1016/s2352-4642(23)00316-4
Molnupiravir or nirmatrelvir–ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · The Lancet Infectious Diseases · 5 citations
https://doi.org/10.1016/s1473-3099(25)00093-3
Economic Evaluation of Using Daily Prednisolone versus Placebo at the Time of an Upper Respiratory Tract Infection for the Management of Children with Steroid-Sensitive Nephrotic Syndrome: A Model-Based Analysis
2022 · PharmacoEconomics - Open · 1 citations
https://doi.org/10.1007/s41669-022-00334-6
Nutritional Characterisation of Childhood Chronic Kidney Disease: Trace Element Malnutrition in Paediatric Renal Disease (TeMPeReD) Study
2025 · Nutrients · 0 citations
https://doi.org/10.3390/nu17030535
Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
2025 · The Lancet Infectious Diseases · 0 citations
https://doi.org/10.1016/s1473-3099(25)00361-5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat